Skip to main
Xander avatar
Xander
@Xander882214
•
#researchshort -ish 🧬 $DNA Ginkgo Bioworks Holdings 🧬 $DNA is a biotech company from the United States founded in 2009 by scientists from MIT and headed by Tom Knight. The company specializes in using genetic engineering to produce bacteria with industrial applications. $DNA is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and is one of the world's largest privately held biotech companies. On 11 May 2021, $DNA announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation. On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be $DNA . The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche. Trading began September 17, 2021. -wiki 💊 Antibiotics 💊 Antibiotic resistance is a growing worldwide problem, endangering thousands of people across the globe and threatening modern medicine. Annually, over 700,000 people die from antibiotic-resistant infections. The United Nations projects that this figure could reach 10 million by 2050 (United Nations IAGC, 2019). Through $DNA 's collaboration with Roche, a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, $DNA is focused on discovering new potential classes of antibacterials. Their method is to mine bacterial genomes for novel pathways, and then engineer these pathways to produce molecules that they can test for antibacterial activity. Their partnership will allow Roche to advance the most successful of these molecules. The integration of their genome mining platform with $DNA 's state of the art sequencing capabilities, extensive biological codebase, bioinformatics and machine learning tools for gene discovery and strain engineering expertise brings forth unprecedented power to accelerate the search for new therapeutics, including next-generation antibiotics. The genomic database includes more than 135,000 bacterial strains. These strains have the potential to encode more than four million biosynthetic gene clusters, which can be used not only for the discovery of novel antibiotics and other therapeutics, but also for applications across food, agriculture and fragrances https://www.ginkgobioworks.com/our-work/combating-antibiotic-resistant-bacteria/ 🥕 Agriculture 🥕 Joyn Bio was founded to create sustainable and cost effective solutions for growers—using microbes. Owned jointly by Leaps by Bayer and $DNA , Joyn leverages Bayer’s expertise in plant biologics and $DNA ’s automated foundry to revolutionize agriculture. Joyn capitalizes on the power of the plant microbiome to improve strains, from pest control to enhanced nutrient acquisition and resistance to crop disease. The plant microbiome is essential for global farming practices, but much of the power of microbes has not yet been tapped into. Primarily housed in $DNA ’s lab space and backed by Ginkgo’s Foundry, Joyn’s team of microbiologists and engineers can test thousands of samples at a time thanks to high throughput automation. This enables systems-level analysis of thousands of strains isolated from soil and rapid prototyping of engineered strains, which are then tested in greenhouse and field conditions at Joyn’s 12,500 square foot testing facility in Woodland, CA. Joyn’s first challenge is reducing the amount of industrial nitrogen fertilizer used to grow crops like corn, wheat, or rice. The industrial production and application of nitrogen fertilizer uses an estimated 3% of total worldwide natural gas and contributes to 3% of global greenhouse gas emissions. By enabling microbes to produce nitrogen in the roots of non-legume crops that can’t fix nitrogen themselves, Joyn could dramatically decrease agriculture’s environmental and energy footprint. Currently, Joyn is putting their engineered, nitrogen-fixing microbes to the test in field trials throughout the US. https://www.ginkgobioworks.com/our-work/joyn-bio/ 🍀 Cannabinoids 🍀 Cannabis is a rapidly growing industry, predicted to reach $57 billion worldwide by 2027. The cannabis plant produces hundreds of different cannabinoids with a range of potential pharmaceutical applications. The most highly concentrated of these compounds are THC and CBD; other molecules such as CBC, CBG, and THCV are present only in minute quantities, making them impractical to extract and purify. While the first two compounds currently constitute over 80% of the current cannabinoid market, rare cannabinoid variants are a significant new market opportunity if they can be produced in pure form at scale with uses ranging from antioxidants to therapeutics. By transferring the DNA sequences for cannabinoid production into organisms such as yeast and E. coli, and using the foundry and our existing high-throughput fermentation processes, $DNA is building strains that produce these cannabinoids at high quality and purity, starting with eight target cannabinoids. The cultured cannabinoids are identical to those extracted from the plant using traditional methods. By capitalizing on the power of biological manufacturing, we can unlock access to medically important cannabinoids that can be scaled up and produced reliably. $CRON a vertically integrated cannabis company, has gathered extensive data on the full spectrum of cannabinoids and their properties to determine the best molecular pathways for synthesizing them. To scale manufacturing of products from this partnership, $CRON has purchased an 84,000 square foot fermentation facility in Winnipeg, Canada. "We’re thrilled to be working with Cronos as they build the world’s most innovative cannabinoid platform." https://www.ginkgobioworks.com/our-work/producing-cultured-cannabinoids/ 🤝 mRNA Victoria and $DNA 🤝 mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and $DNA , the leading horizontal platform for cell programming, today announced a partnership to support vaccine development, biosecurity initiatives, and the application to $DNA 's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first step in the partnership, Ginkgo will establish an office in Melbourne in what is hoped to be a future long-term business expansion within Australia. $DNA 's synthetic biology platform infrastructure and expertise brings critical capability to Victoria's biotech sector, and adds significant momentum to the State's rapidly growing biotechnology ecosystem. $DNA 's cell programming capabilities have supported innovations in diagnostics and vaccine design and manufacturing, as well as ongoing research and development of innovative products such as living medicines, therapeutic proteins, and gene and cell therapies. Further, the company has established one of the largest nationwide COVID testing platforms in the United States, helping communities across the country keep kids in classrooms and COVID out. The company has also established an Airport Biosurveillance Program in collaboration with XpresCheck and the Centers for Disease Control and Prevention (CDC). "Melbourne is one of the leading biomedical research communities in the world. We have to forge international collaborations like this because, as we have all learned, biology doesn't respect borders. We are incredibly excited to work with mRNA Victoria and hope to expand further into the Australian market," said Matt McKnight, Chief Commercial Officer, Ginkgo Bioworks. Victoria is a leader in mRNA research and manufacturing in Australia, with the nation's most sophisticated and largest mRNA ecosystem and commercialization capability. Through mRNA Victoria, the Victorian Government will continue to attract world leading biotech innovators to invest in Victoria, creating new jobs and fostering innovation in novel RNA treatments. "Victoria has a strong RNA ecosystem and is ideally placed to develop a sophisticated supply chain with critical capability from clinical development to the establishment of onshore mRNA manufacturing to the critical biosecurity technologies that enable us to reopen borders and get back to our lives," said Jaala Pulford, Victoria's Minister for Innovation, Medical Research and the Digital Economy. https://finance.yahoo.com/news/mrna-victoria-ginkgo-bioworks-announce-120000507.html
10
0
Own your future.
Build your portfolio.

Invest in everything on Public

Public is an all-in-one investing platform where you can build a multi-asset portfolio that includes everything from stocks and options to bonds, crypto, and a High-Yield Cash Account.
Sign Up
Contact Us
Check the background of this firm on FINRA’s BrokerCheck.
Open to the Public Investing, Inc. Customer Relationship Summary

© Copyright 2024 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

Stocks, ETFs, Options, Bonds.
Self-directed brokerage accounts and brokerage services for US-listed, registered securities, options, and Bonds, except for treasury securities offered through Jiko Securities, Inc., are offered to self-directed customers by Open to the Public Investing, Inc. (“Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Public Investing is not registered. Securities products offered by Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Additional information can be found here.

Options.
Certain requirements must be met in order to trade options. Options can be risky and are not suitable for all investors. Options transactions are often complex, and investors can rapidly lose the entire amount of their investment or more in a short period of time. Investors should consider their investment objectives and risks carefully before investing in options. Refer to the Characteristics and Risks of Standardized Options before considering any options transaction. Supporting documentation for any claims, if applicable, will be furnished upon request. Tax considerations with options transactions are unique and investors considering options should consult their tax advisor as to how taxes affect the outcome of each options strategy.

Options Order Flow Rebates.
If you are enrolled in our Options Order Flow Rebate Program, Public Investing will share a percentage of our estimated order flow revenue for each completed options trade as a rebate to help reduce your trading costs. Rebate rates vary monthly from $0.06-$0.18 and depend on your current and prior month’s options trading volume. This rebate will be deducted from your cost to place the trade and will be reflected on your trade confirmation. To learn more, see our Options Rebate Program Terms & Conditions, Order Rebate FAQ and Fee Schedule.

Bonds.
“Bonds” shall refer to corporate debt securities and U.S. government securities offered on the Public platform through a self-directed brokerage account held at Public Investing and custodied at Apex Clearing. For purposes of this section, Bonds exclude treasury securities held in treasury accounts with Jiko Securities, Inc. as explained under the “ Treasury Accounts” section.

Investments in Bonds are subject to various risks including risks related to interest rates, credit quality, market valuations, liquidity, prepayments, early redemption, corporate events, tax ramifications and other factors. The value of Bonds fluctuate and any investments sold prior to maturity may result in gain or loss of principal. In general, when interest rates go up, Bond prices typically drop, and vice versa. Bonds with higher yields or offered by issuers with lower credit ratings generally carry a higher degree of risk. All fixed income securities are subject to price change and availability, and yield is subject to change. Bond ratings, if provided, are third party opinions on the overall bond's credit worthiness at the time the rating is assigned. Ratings are not recommendations to purchase, hold, or sell securities, and they do not address the market value of securities or their suitability for investment purposes.

A Bond Account is a self-directed brokerage account with Public Investing. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The Bond Account’s yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees. A bond’s yield is a function of its market price, which can fluctuate; therefore a bond’s YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our Fee Schedule.

Bond Accounts are not recommendations of individual bonds or default allocations. The bonds in the Bond Account have not been selected based on your needs or risk profile. You should evaluate each bond before investing in a Bond Account. The bonds in your Bond Account will not be rebalanced and allocations will not be updated, except for Corporate Actions.

Fractional Bonds also carry additional risks including that they are only available on Public and cannot be transferred to other brokerages. Read more about the risks associated with fixed income and fractional bonds. See Bond Account Disclosures to learn more.

High-Yield Cash Account.
A High-Yield Cash Account is a secondary brokerage account with Public Investing. Funds in your High-Yield Cash Account are automatically deposited into partner banks (“Partner Banks”), where that cash earns interest and is eligible for FDIC insurance. See here for a list of current Partner Banks. Your Annual Percentage Yield is variable and may change at the discretion of the Partner Banks or Public Investing. Apex Clearing and Public Investing receive administrative fees for operating this program, which reduce the amount of interest paid on swept cash. Neither Public Investing nor any of its affiliates is a bank. Learn more.

Cryptocurrency.
Cryptocurrency trading, execution, and custody services are provided by Bakkt Crypto Solutions, LLC (NMLS ID 1828849) (“Bakkt”). Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrencies offered by Bakkt are not securities and are not FDIC insured or protected by SIPC. Your cryptocurrency assets are held in your Bakkt account. Bakkt is a licensed virtual currency business by the New York State Department of Financial Services and a licensed money transmitter, but is not a registered broker-dealer or a FINRA member. Your Bakkt Crypto account is separate from your brokerage account with Public Investing, which holds US-listed stocks and ETFs. Please review the Risk Disclosures before trading.

Treasury Accounts.
Investing services in treasury accounts offering 6 month US Treasury Bills on the Public platform are through Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). T-bills are purchased at a discount to the par value and the T-bill’s yield represents the difference in price between the “par value” and the “discount price.” Aggregate funds in your Treasury Account in excess of the T-bill purchases will remain in your Treasury Account as cash. The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability - yield is subject to change. Past performance is not indicative of future performance. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. Although T-bills are considered safer than many other financial instruments, you could lose all or a part of your investment. See Jiko U.S. Treasuries Risk Disclosures for further details.

Investments in T-bills: Not FDIC Insured; No Bank Guarantee; May Lose Value.

Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

Commission-free trading refers to $0 commissions charged on trades of US listed registered securities placed during the US Markets Regular Trading Hours in self-directed brokerage accounts offered by Public Investing. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more.

Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more.

Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for informational purposes only and are meant as helpful starting points as you discover, research and create a Plan that meets your specific investing needs. Plans are self-directed purchases of individually-selected assets, which may include stocks, ETFs and cryptocurrency. Plans are not recommendations of a Plan overall or its individual holdings or default allocations. Plans are created using defined, objective criteria based on generally accepted investment theory; they are not based on your needs or risk profile. You are responsible for establishing and maintaining allocations among assets within your Plan. Plans involve continuous investments, regardless of market conditions. Diversification does not eliminate risk. See our Investment Plans Terms and Conditions and Sponsored Content and Conflicts of Interest Disclosure.

Alpha.
Alpha is an experiment brought to you by Public Holdings, Inc. (“Public”). Alpha is an AI research tool powered by GPT-4, a generative large language model. Alpha is experimental technology and may give inaccurate or inappropriate responses. Output from Alpha should not be construed as investment research or recommendations, and should not serve as the basis for any investment decision. All Alpha output is provided “as is.” Public makes no representations or warranties with respect to the accuracy, completeness, quality, timeliness, or any other characteristic of such output. Your use of Alpha output is at your sole risk. Please independently evaluate and verify the accuracy of any such output for your own use case.

Market Data.
Quotes and other market data for Public’s product offerings are obtained from third party sources believed to be reliable, but Public makes no representation or warranty regarding the quality, accuracy, timeliness, and/or completeness of this information. Such information is time sensitive and subject to change based on market conditions and other factors. You assume full responsibility for any trading decisions you make based upon the market data provided, and Public is not liable for any loss caused directly or indirectly by your use of such information. Market data is provided solely for informational and/or educational purposes only. It is not intended as a recommendation and does not represent a solicitation or an offer to buy or sell any particular security.

View Full Disclosures